SPARX TECHNOLOGIES
The SparX SAILINGTM Multi-specific Antibody Discovery Platform
Synthetic Multidimension-programmed Antibody (SynMabTM)
News
- Fosun veteran Juxiang Xia joins Sparx TherapeuticsAugust 10th, 2021 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibody and antibody-drug conjugate (ADC) drugs, today announced Continue Reading
- Sparx Therapeutics Is Building its First Commercial Manufacturing Facility for Its Antibody Drug ProductionJuly 8th, 2021 Sparx Therapeutics (Mount Prospect, IL, USA) announced a plan to build a 1,200,000-square-foot manufacturing facility in Yangzhou, Continue Reading
- Former Eli Lilly veteran Dr. Victor Wroblewski joins Sparx Therapeutics as a Senior VP and Head of BiologyChicago，USA September 1, 2020 Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today Continue Reading
- Sparx Therapeutics-News release 2018-11-8Sparx Therapeutics & KPC Pharmaceutical Sign Agreement for the Development of anti-Claudin 18.2 Antibodies Sparx Therapeutics, Inc. has signed an Continue Reading
- Precision Medicine Center UnveiledChina, Sep-10-2018 Central South University Xiangya - Yaoyuan Pharma Precision Medicine Research Center has just been officially founded today. This Continue Reading